PharmaBlock Sciences Nanjing Inc Class A - Asset Resilience Ratio
PharmaBlock Sciences Nanjing Inc Class A (300725) has an Asset Resilience Ratio of 8.00% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check PharmaBlock Sciences Nanjing Inc Class A (300725) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how PharmaBlock Sciences Nanjing Inc Class A's Asset Resilience Ratio has changed over time. See debt-free asset ratio of PharmaBlock Sciences Nanjing Inc Class A to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down PharmaBlock Sciences Nanjing Inc Class A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 300725 company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥623.53 Million | 8.0% |
| Total Liquid Assets | CN¥623.53 Million | 8.00% |
Asset Resilience Insights
- Limited Liquidity: PharmaBlock Sciences Nanjing Inc Class A maintains only 8.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
PharmaBlock Sciences Nanjing Inc Class A Industry Peers by Asset Resilience Ratio
Compare PharmaBlock Sciences Nanjing Inc Class A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 1.28% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Procter & Gamble Health Limited
NSE:PGHL |
Drug Manufacturers - Specialty & Generic | 33.01% |
Annual Asset Resilience Ratio for PharmaBlock Sciences Nanjing Inc Class A (2014–2024)
The table below shows the annual Asset Resilience Ratio data for PharmaBlock Sciences Nanjing Inc Class A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 9.43% | CN¥465.61 Million ≈ $68.13 Million |
CN¥4.94 Billion ≈ $722.19 Million |
-11.91pp |
| 2023-12-31 | 21.35% | CN¥1.09 Billion ≈ $159.44 Million |
CN¥5.10 Billion ≈ $746.88 Million |
+17.99pp |
| 2022-12-31 | 3.36% | CN¥163.30 Million ≈ $23.90 Million |
CN¥4.86 Billion ≈ $711.49 Million |
-5.32pp |
| 2021-12-31 | 8.68% | CN¥304.43 Million ≈ $44.55 Million |
CN¥3.51 Billion ≈ $513.17 Million |
+4.24pp |
| 2020-12-31 | 4.44% | CN¥107.62 Million ≈ $15.75 Million |
CN¥2.43 Billion ≈ $354.90 Million |
+2.35pp |
| 2019-12-31 | 2.09% | CN¥21.52 Million ≈ $3.15 Million |
CN¥1.03 Billion ≈ $150.60 Million |
+0.12pp |
| 2014-12-31 | 1.97% | CN¥2.00 Million ≈ $292.66K |
CN¥101.56 Million ≈ $14.86 Million |
-- |
About PharmaBlock Sciences Nanjing Inc Class A
PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services throughout the pharmaceutical research and development, and commercial manufacturing in China and internationally. It offers medicinal chemistry-oriented SAR/SPR tool kits for molecule design; building blocks enabled libraries, including fragment-based drug discovery, DNA encoded library technology, and mega virtual lib… Read more